Courts continue to rule in favor of Lilly’s lung cancer treatment patent, as the District Court for Appeals concludes generic producers like Dr Reddy’s to be potentially infringing.
Aurobindo Pharma Limited has denied rumours it is interested in Orchid Pharma after a report suggested it is vying with Dr Reddy’s to acquire the bankrupt API firm.
Dr Reddy's says efforts to fix plant problems flagged by US FDA impacted its active pharmaceutical ingredient (API) business in the first quarter of fiscal 2018.
The US FDA has identified problems at Dr Reddy’s generic drug manufacturing site in Bachupally, India according to a filing on the Bombay Stock Exchange (BSE).
The US FDA has completed its inspection of Dr Reddy’s API plant in Srikakulam, Andhra Pradesh and issued the firm with a Form 483 detailing two observations.
Mezzion has hired Pol Pharma and Halo Pharma and accused former CMO Dr Reddy’s of hiding manufacturing problems that cost its erectile dysfunction candidate, udenafil, US approval.
Dr Reddy’s has changed the colour of its Nexium generic capsules from purple to blue in a bid to resume US sales, as litigation with AstraZeneca continues.
In the second setback for Dr Reddy’s within a week, the District Court of Delaware has granted a temporary restraining order preventing the company from selling esomeprazole, the generic version of AstraZeneca’s Nexium.
Dr Reddy’s Laboratories says accusations by the US Government’s Consumer Product Safety Commission (CPSC) that it violated childproof packaging rules could cause significant losses for the company.
Dr. Reddy’s may not have as big a hill to climb as some observers suggest to regain customers lost as a result of the closure of its Mexican API plant, according to Barclays.
GlaxoSmithKline will sell its oral penicillin manufacturing facility in Tennessee, US, to Dr Reddy’s for an undisclosed sum, along with US rights to its Augmentin and Amoxin brands.
Dr Reddy’s has made a “significant investment” in an mPEG alcohol production facility in Mexico to strengthen its presence in a sector it believes is on the rise.
Dr Reddy’s Laboratories is combining some of its products with Aegis Therapeutics’ Intravail drug delivery technology after the companies entered into a partnership.
India's Dr Reddy's Laboratories has just announced the signing of a
definitive agreement to buy the US pharmaceutical contract
manufacturing business of chemicals giant BASF.
Three of India´s large pharmaceutical manufacturers, Dr Reddy's,
Ranbaxy Laboratories and Shilpa Medicare have just announced new
merger and acquisition (M&A) deals.
UK drug delivery specialist SkyePharma has signed an agreement with
India's Dr Reddy's Laboratories for a feasibility study of an
unnamed product using two of SkyePharma's proprietary drug delivery
systems.
India-based Dr Reddy's Laboratories has boosted its revenue by 168
per cent for the 2006 year, fuelled by a strengthening position in
the international market.
Dr Reddy's Laboratories has boosted its ability to serve Western
pharmaceutical markets with an increase in its manufacturing
capacity for drug formulations.
Dr Reddy's Laboratories has started first clinical trials of a
"four-in-one" polypill clinical trial, which could revolutionise
the cardiovascular drugs market.
ClinTec International and Dr. Reddy's Laboratories have announced a
partnership, in which both parties are to jointly develop an
anti-cancer drug that belongs to the topoisomerase inhibitors class
of compounds.
Dr. Reddy's Laboratories has announced the inauguration of its
seventh finished dosage plant in India, reflecting the country's
unprecedented growth as a generic pharmaceuticals manufacturer.
India's Dr Reddy's Laboratories has acquired a US company that
brings in a proprietary drug delivery technology that could be
applied across a whole range of dermatological products.
Earlier this week, the US Food and Drug Administration suspended
the approval of a generic version of Pfizer's high blood pressure
drug Norvasc (amlodipine besylate) developed by India's Dr Reddy's
Laboratories. The...
Hyderabad, India-based Dr Reddy's Laboratories has reported
revenues of 5.1 billion rupees (€89m) in the third quarter of
fiscal 2004, up 18 per cent and ahead of analysts' forecasts.
Dr Reddy's Laboratories has developed a new class of therapeutic
that could make it the first pharmaceutical company in India to
develop a proprietary blockbuster product.
